HUB Organoids
HUB Organoids is a pioneering biotechnology company specializing in the application of Organoid Technology to drug discovery, personalized medicine, and disease modeling. Founded in 2013 following the discovery of adult stem cells, HUB´s drug development platform uses advanced 3D organoid models derived from patient tissues, enabling more accurate and predictive research for preclinical testing and therapeutic development. HUB´s innovative platform accelerates the discovery of effective treatments by closely mimicking human biology and is available on a fee for service basis to scientists working in drug discovery and development in the therapeutic areas of oncology, inflammation/IBD, infectious diseases, and for toxicology investigation. HUB is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the US and Canada.
